Irradiation of regional lymph node areas in breast cancer – Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design (2020) Borm KJ, Oechsner M, Duesberg M, Buschner G, Weber W, Combs SE, Dumaa MN Journal article Application of presurgical navigated transcranial magnetic stimulation motor mapping for adjuvant radiotherapy planning in patients with high-grade gliomas (2019) Diehl CD, Schwendner MJ, Sollmann N, Oechsner M, Meyer B, Combs SE, Krieg SM Journal article Deep learning derived tumor infiltration maps for personalized target definition in Glioblastoma radiotherapy (2019) Peeken JC, Molina-Romero M, Diehl C, Menze BH, Straube C, Meyer B, Zimmer C, et al. Journal article Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma (2019) Fleischmann DF, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, Unterrainer M, et al. Journal article CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy (2019) Peeken JC, Bernhofer M, Spraker MB, Pfeiffer D, Deyecka M, Thamer A, Shouman MA, et al. Journal article Impact of inter- and intra-observer variabilities of catheter reconstruction on multi-catheter interstitial brachytherapy of breast cancer patients (2019) Kallis K, Kaltsas T, Kreppner S, Lotter M, Strnad V, Fietkau R, Bert C Journal article Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution Radiotherapy with paclitaxel/cisplatin vs. fluorouracil/cisplatin for head and neck cancer (2019) Fietkau R, Hecht M, Hofner B, Iro H, Gefeller O, Roedel C, Hautmann M, et al. Conference contribution QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04) (2019) Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, et al. Conference contribution Neutrophilia as prognostic factor for outcome in the CAO/ARO/ALO-04 phase 3 rectal cancer trial (2019) Diefenhardt M, Hofheinz R, Beissbarth T, Arnold D, Von Den Gruen JM, Liersch T, Stroebel P, et al. Conference contribution